nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.10.2019 | Review Article

Genital Psoriasis: Impact on Quality of Life and Treatment Options

verfasst von: Aine Kelly, Caitriona Ryan

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis involving the genital skin occurs in up to two-thirds of psoriasis patients but is often overlooked by physicians. Furthermore, psoriasis objective and subjective severity indexes for common plaque psoriasis often neglect the impact this small area of psoriasis can have on a patient. It can have a significant impact on patients’ psychosocial function due to intrusive physical symptoms such as genital itch and pain, and a detrimental impact on sexual health and impaired relationships. The mainstay of treatment is topical therapy. In patients with genital psoriasis refractory to traditional topical treatment, biologic treatments may greatly improve patient outcomes.

Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978–83. https://doi.org/10.1016/j.jaad.2015.02.1127.CrossRefPubMed

Sobarun P. Genital psoriasis. https://www.dermnetnz.org/topics/genital-psoriasis. Accessed 8 May 2019.

Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol. 2008;9(2):111–7. https://doi.org/10.2165/00128071-200809020-00004.CrossRefPubMed

Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41–7.PubMedPubMedCentral

Saraswat PK, Garg A, Mishra D, Garg S. A study of pattern of nonvenereal genital dermatoses of male attending skin OPD at a tertiary care center. Indian J Sex Transm Dis AIDS. 2014;35(2):129–34. https://doi.org/10.4103/0253-7184.142408.CrossRefPubMedPubMedCentral

Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392–8. https://doi.org/10.5114/reum.2018.80718.CrossRefPubMedPubMedCentral

Mahajan R, Kumaran MS, Narang T, Handa S, Dogra S. Genital psoriasis among Indians: a prospective cross-sectional study. Australas J Dermatol. 2015;56(1):e18–20. https://doi.org/10.1111/ajd.12077.CrossRefPubMed

Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011;91(1):5–11. https://doi.org/10.2340/00015555-0988.CrossRefPubMed

Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, Dutronc Y, Henneges C, Kornberg LJ, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatol Treat. 2018;29(8):754–60. https://doi.org/10.1080/09546634.2018.1453125.CrossRef

10.

Wang G, Li C, Gao T, Liu Y. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. Eur J Dermatol. 2005;15(3):176–8.PubMed

11.

Lysell J, Tessma M, Nikamo P, Wahlgren CF, Stahle M. Clinical characterisation at onset of childhood psoriasis—a cross sectional study in Sweden. Acta Derm Venereol. 2015;95(4):457–61. https://doi.org/10.2340/00015555-1986.CrossRefPubMed

12.

Larsabal M, Ly S, Sbidian E, Moyal-Barracco M, Dauendorffer JN, Dupin N, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019;180(3):647–56. https://doi.org/10.1111/bjd.17147.CrossRefPubMed

13.

Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6. https://doi.org/10.1111/j.1468-3083.2005.01329.x.CrossRefPubMed

14.

Meeuwis KA, de Hullu JA, de Jager ME, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands. J Eur Acad Dermatol Venereol. 2010;24(12):1425–30. https://doi.org/10.1111/j.1468-3083.2010.03663.x.CrossRefPubMed

15.

van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200(4):292–8. https://doi.org/10.1159/000018390.CrossRefPubMed

16.

Ljosaa TM, Rustoen T, Mork C, Stubhaug A, Miaskowski C, Paul SM, et al. Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. Acta Derm Venereol. 2010;90(1):39–45. https://doi.org/10.2340/00015555-0764.CrossRefPubMed

17.

Meeuwis KA, van de Kerkhof PC, Massuger LF, de Hullu JA, van Rossum MM. Patients’ experience of psoriasis in the genital area. Dermatology. 2012;224(3):271–6. https://doi.org/10.1159/000338858.CrossRefPubMed

18.

Bolognia JL, Schaffer JV, Cerroni L. Dermatology, vol 1. 4th ed. Elsevier; 2018.

19.

Albert S, Neill S, Derrick EK, Calonje E. Psoriasis associated with vulval scarring. Clin Exp Dermatol. 2004;29(4):354–6. https://doi.org/10.1111/j.1365-2230.2004.01505.x.CrossRefPubMed

20.

Borghi A, Virgili A, Corazza M. Dermoscopy of inflammatory genital diseases: practical insights. Dermatol Clin. 2018;36(4):451–61. https://doi.org/10.1016/j.det.2018.05.013.CrossRefPubMed

21.

Kapila S, Bradford J, Fischer G. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Low Genit Tract Dis. 2012;16(4):364–71. https://doi.org/10.1097/LGT.0b013e31824b9e5e.CrossRefPubMed

22.

Hong J, Bernstein D. A review of drugs that induce or exacerbate psoriasis. Psoriasis Forum. 2012;18a(1):2–11. https://doi.org/10.1177/247553031218a00101.CrossRef

23.

McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol. 1997;36(3 Pt 1):388–94.CrossRef

24.

Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47(4):512–8.CrossRef

25.

Root S, Kent G, al-Abadie MS. The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology. 1994;189(3):234–7. https://doi.org/10.1159/000246844.CrossRef

26.

Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof PC, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164(6):1247–55. https://doi.org/10.1111/j.1365-2133.2011.10249.x.CrossRefPubMed

27.

Cather JC, Ryan C, Meeuwis K, Potts Bleakman AJ, Naegeli AN, Edson-Heredia E, et al. Patients’ perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther (Heidelb). 2017;7(4):447–61. https://doi.org/10.1007/s13555-017-0204-3.CrossRefPubMedPubMedCentral

28.

Turel Ermertcan A, Temeltas G, Deveci A, Dinc G, Guler HB, Ozturkcan S. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33(11):772–8. https://doi.org/10.1111/j.1346-8138.2006.00179.x.CrossRefPubMed

29.

Bardazzi F, Odorici G, Ferrara F, Magnano M, Balestri R, Patrizi A. Sex and the PASI: patients affected by a mild form of psoriasis are more predisposed to have a more severe form of erectile dysfunction. J Eur Acad Dermatol Venereol. 2016;30(8):1342–8. https://doi.org/10.1111/jdv.13625.CrossRefPubMed

30.

Zhao S, Wang J, Xie Q, Liu Y, Luo L, Zhu Z, et al. High prevalence of erectile dysfunction in men with psoriasis: evidence from a systematic review and meta-analysis. Int J Impot Res. 2019;31(2):74–84. https://doi.org/10.1038/s41443-018-0093-8.CrossRefPubMed

31.

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, et al. The development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to assess the impact of genital psoriasis on sexual health. Dermatol Ther (Heidelb). 2018;8(1):33–44. https://doi.org/10.1007/s13555-017-0212-3.CrossRefPubMed

32.

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, et al. The development of a patient-reported outcome measure for assessment of genital psoriasis symptoms: the Genital Psoriasis Symptoms Scale (GPSS). Dermatol Ther (Heidelb). 2017;8(1):45–56. https://doi.org/10.1007/s13555-017-0213-2.CrossRefPubMedPubMedCentral

33.

Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, et al. The Static Physician’s Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol. 2017;16(8):793–9.PubMed

34.

Farage MA, Warren R. Emollients on the genital area. Curr Probl Dermatol. 2011;40:101–6. https://doi.org/10.1159/000321059.CrossRefPubMed

35.

Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther (Heidelb). 2018;8(4):509–25. https://doi.org/10.1007/s13555-018-0257-y.CrossRefPubMedPubMedCentral

36.

Meeuis KA, de Hullu JA, IntHout J, Hendriks IM, Sparreboom EE, Massuger LF, et al. Genital psoriasis awareness program: physical and psychological care for patients with genital psoriasis. Acta Derm Venereol. 2015;95(2):211–6. https://doi.org/10.2340/00015555-1885.CrossRef

37.

Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of inverse/intertriginous psoriasis: updated guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017;16(8):760–6.PubMed

38.

Weinrauch L, Katz M. Psoriasis vulgaris of labium majus. Cutis. 1986;38(5):333–4.PubMed

39.

Usatine RP. Itchy rash in groin. J Fam Pract. 2016;65(11).

40.

Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg. 2008;12(5):230–4. https://doi.org/10.2310/7750.2008.07055.CrossRefPubMed

41.

Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E, Karpouzis A, et al. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res. 2005;31(4):141–5.

42.

Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g⁻¹ ointment and tacrolimus 0.3 mg g⁻¹ ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007;157(5):1005–12. https://doi.org/10.1111/j.1365-2133.2007.08201.x.CrossRef

43.

Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med. 1990;322(16):1093–7. https://doi.org/10.1056/nejm199004193221601.CrossRef

44.

Singh N, Thappa DM. Circinate pustular psoriasis localized to glans penis mimicking ‘circinate balanitis’ and responsive to dapsone. Indian J Dermatol Venereol Leprol. 2008;74(4):388–9.CrossRef

45.

Guglielmetti A, Conlledo R, Bedoya J, Ianiszewski F, Correa J. Inverse psoriasis involving genital skin folds: successful therapy with dapsone. Dermatol Ther (Heidelb). 2012;2(1):15. https://doi.org/10.1007/s13555-012-0015-5.CrossRefPubMedPubMedCentral

46.

Barranquero Fernández A, Suárez Pérez JA, Herrera Acosta E, Mendiola Fernández MV, Herrera Ceballos E. Apremilast in the therapy of moderate to severe chronic plaque psoriasis and special locations [abstract]. J Am Acad Dermatol. 2017;76(6):AB46. https://doi.org/10.1016/j.jaad.2017.04.200.

47.

Celgene. An efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe genital psoriasis (DISCREET) [ClinicalTrials.gov identifier NCT03777436]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 18 June 2019

48.

Jese R, Perdan-Pirkmajer K, Dolenc-Voljc M, Tomsic M. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat. 2014;23(1):21–3.PubMed

49.

Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, et al. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J Dermatol Treat. 2018;29(5):481–6. https://doi.org/10.1080/09546634.2017.1395805.CrossRef

50.

Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–36. https://doi.org/10.1111/bjd.15665.CrossRefPubMed

51.

Cassano N, Mastrandrea V, Buquicchio R, Miracapillo A, Loconsole F, Filotico R, et al. Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice. J Biol Regul Homeost Agents. 2008;22(3):185–93.PubMed

52.

FDA statement on the voluntary withdrawal of Raptiva from the US market. 8 Apr 2009. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-statement-voluntary-withdrawal-raptiva-us-market. Accessed 18 June 2019.

53.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844–52. https://doi.org/10.1111/bjd.16736.CrossRefPubMed

54.

Yosipovitch G, Foley P, Ryan C, Cather JC, Meeuwis KA, Burge R, et al. Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study. J Sex Med. 2018;15(11):1645–52. https://doi.org/10.1016/j.jsxm.2018.09.004.CrossRefPubMed

55.

Galluzzo M, Talamonti M, De Simone C, D’Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–35. https://doi.org/10.1080/14712598.2018.1481503.CrossRefPubMed

Titel: Genital Psoriasis: Impact on Quality of Life and Treatment Options
verfasst von: Aine Kelly
Caitriona Ryan
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 5/2019
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-019-00447-5

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Pediatric Laser Therapy in Pigmented Conditions

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council

Biologic Treatment for Hidradenitis Suppurativa

Vascular Tests for Dermatologists

Authors’ Reply to Cerejeira: "Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database"